Cleveland Clinic Launches First-of-its Kind Preventive Breast Cancer Vaccine Study

Cleveland Clinic Launches First-of-its Kind Preventive Breast Cancer Vaccine Study

(MENAFN- Mid-East. Info) Cleveland, Ohio: Researchers from a top American hospital, Cleveland Clinic, have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. This phase I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body's immune response. The U. S. Food and Drug Administration recently approved an investigational new drug application for the vaccine, which permits Cleveland Clinic and partner Anixa Biosciences, Inc. (ANIX:NASDAQ) to start the study. "We are hopeful that this research will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive type of breast cancer," said G. Thomas Budd, M. D., of Cleveland Clinic's Taussig Cancer Institute and principal investigator of the study."Long term, we are hoping that this can be a true preventive vaccine that would be administered to healthy women to prevent them from developing triple-negative breast cancer, the form of breast cancer for which we have the least effective treatments." There is a great need for improved treatments for triple-negative breast cancer, which does not have